Using CBD to reduce pain in knee osteoarthritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of orally dissolving cannabidiol (CBD) tablets in reducing pain and improving function in patients with knee osteoarthritis. It is a multi-center, double-blinded, randomized, placebo-controlled trial comparing outcomes between patients receiving CBD and those receiving a placebo while undergoing physiotherapy and home exercises. Participants will rate their pain and satisfaction at multiple time points throughout the treatment period to assess the impact of CBD on their condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients presenting with knee osteoarthritis (KL Grade II-III)
* Knee pain for at least three months, occurring in at least half of the days in that period
* VAS ≥ 4
* Patients ages 40-75, inclusive
* If female patients are pre-menopausal they must be currently practicing effective forms of two types of birth control, which are defined as those, alone or in combination, that result in a low failure rate (less than 1% per year) when used consistently and correctly
* Male patients must be using an effective form of contraception

Exclusion Criteria:

* Knee Injections within the last 3 months (cortisone, PRP, hyaluronic acid)
* Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects, dementia, etc.)
* Younger than 40 years of age
* Older than 75 years of age
* Any patient considered a vulnerable subject: pregnant women or fetuses, children, cognitively impaired adults, prisoners
* History of cannabis abuse or dependence
* History of coagulation abnormalities and thromboembolic disease or current abnormal coagulation test values
* History of stroke or acute coronary syndromes within 3 months
* Abnormal coagulation profile
* Renal failure (serum creatinine \> 250 μmol/L \[2.83 mg/dL\]) or liver cirrhosis
* Patients that have been on opioid management for any reason just prior to the study
* Patients with known inflammatory arthritis (such as rheumatoid arthritis, gout, pseudogout etc)
* Patients with a large effusion
* Patients with a BMI \> 35
* Patients meeting the DSM-V for major psychiatric illness, such as bipolar disorder
* Patients diagnosed with major depression, psychosis, or substance abuse disorder
* Patients with current or a history of suicidal ideation
* Breastfeeding females
* Abnormal LFTs
* Patients with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain/head injury, or seizures
* Patients with moderate (Child-Pugh B) and severe hepatic impairment (Child-Pugh C).
* Patients taking moderate or strong inhibitors of CYP3A4 and CYP2C19 (listed below) concomitantly will be considered for exclusion if determined to be clinically significant by the treating physicians
* Patients taking strong CYP3A4 and CYP2C19 inducers (listed below) concomitantly will be considered for exclusion if determined to be clinically significant by the treating physicians
* Patients taking substrates of UTG1A9, UTGB17, CYP2A1, CYP2B6, CYP2C8, CYP2C9 and CYP2C19 (listed below) concomitantly will be considered for exclusion if determined to be clinically significant by the treating physicians

Where it's running

• NYU Langone Health
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Michael J Alaia, MD — NYU Langone Health
• Study coordinator: Michael J Alaia, MD
• Email: michael.alaia@nyulangone.org
• Phone: 646-501-7223

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Observational study on outcomes after hip and knee replacements

  This study looks at how people feel and do after getting hip and knee replacements to find ways to improve their care in the future.

  Recruiting Northumbria Healthcare NHS Foundation Trust · Ashington · NCT05824845

• Evaluating a new surgical irrigation method for joint replacement surgeries

  This study is testing a new way to clean the surgical area during knee or hip replacement surgeries to see if it can lower the risk of infections compared to the usual method.

  Recruiting at 8 sites Ottawa Hospital Research Institute · Vancouver, British Columbia and 7 other locations · NCT05543941

• Medial unloader brace after root repair

  This study tests whether using a medial unloader brace after arthroscopic medial meniscus posterior root repair helps healing and improves knee outcomes.

  Recruiting NYU Langone Health · New York, New York · NCT07909369

• MAC-STILA: a feasibility test for hip fracture surgery anesthesia

  This trial tests whether combining monitored anesthesia care with soft tissue infiltration using local anesthesia can reduce post-operative delirium in adults 65 and older undergoing hip fracture repair.

  Recruiting NYU Langone Health · Evanston, Illinois and 4 other locations · NCT07897656

• Osimertinib with Cyclosporine A for EGFR-mutant NSCLC

  This phase II study tests whether adding cyclosporine A to osimertinib helps people with EGFR-mutant metastatic NSCLC who still have detectable tumor DNA in blood.

  Recruiting Phase 2 NYU Langone Health · New York, New York · NCT07874490

• Histotripsy with chemotherapy and immunotherapy for biliary tract cancer

  This pilot test will see if adding histotripsy to chemoimmunotherapy is safe and feasible for adults with biliary tract cancer.

  Recruiting NYU Langone Health · New York, New York · NCT07853690

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.